News

As per the agreement, GSK will pay research funding as well as a sum of $20m as an upfront payment to Epizyme. Additionally, GSK is also responsible to

Watson Pharma said that the approved drug is generic equivalent to Cephalon’s Fentora tablets. Fentora is used to treat breakthrough pain in adult patients with cancer (18 years

Emerald and UCB had initiated their collaboration partnership in January 2009. Under the agreement, both the companies have identiified a series of small molecules and have solved high-resolution

Davanat is a polysaccharide polymer that targets Galectin receptors on cancer cells and interferes with their activity. Pro-Pharma has fixed the primary endpoint of the trial as the

Fentanyl immediate-release transmucosal medications are administered on the soft surfaces of the mouth or the nasal passages or throat where they dissolve and are absorbed. Abstral is indicated

Under the agreement, TD2 – a subsidiary of Translational Genomics Research Institute (TGen), will be the exclusive development partner for Oncoholdings’ oncology portfolio. The company plans to develop

UCB has initiated a new Phase III study assessing brivaracetam as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. The randomised, double-blind, placebo-controlled,

The ‘LifeSciencesUK’ is expected to allow biotechnology, pharmaceuticals, medical devices and diagnostics sectors to jointly funtion smoothly to better investment environment in the UK, reported Pharmacy Europe. ‘LifeSciencesUK’

The study will recruit around 200 patients and will evaluate the safety, tolerability and antiviral activity of CMX001. The primary objective of CMX001 study is to provide CMX001